Mission Statement, Vision, & Core Values of PROCEPT BioRobotics Corporation (PRCT)

The Mission Statement, Vision, and Core Values of PROCEPT BioRobotics Corporation aren't just corporate boilerplate; they are the strategic engine driving its impressive financial momentum, projecting full-year 2025 revenue guidance of approximately $325.5 million, a 45% year-over-year growth. That kind of growth, plus an installed U.S. base of 653 robotic systems as of Q3 2025, forces you to ask: how does a commitment to Excellence and Ingenuity translate into tangible shareholder value, even while managing an Adjusted EBITDA loss of around ($35.0 million) this year? Understanding the 'why' behind their goal to revolutionize BPH treatment is defintely key to mapping their near-term risks and long-term opportunity.

PROCEPT BioRobotics Corporation (PRCT) Overview

PROCEPT BioRobotics Corporation is a surgical robotics company, founded in 2007, that's focused on transforming urology care, specifically for benign prostatic hyperplasia (BPH), or an enlarged prostate. Their flagship product is the AquaBeam Robotic System, which delivers a minimally invasive treatment called Aquablation therapy. This system uses a heat-free, image-guided waterjet to remove prostate tissue, offering a precise alternative to traditional surgery.

The company's revenue stream is a classic razor-and-blade model, relying on the sale of the capital equipment-the AquaBeam or the next-generation HYDROS Robotic System-plus the recurring revenue from single-use handpieces and consumables used in each procedure. For the full fiscal year 2025, PROCEPT BioRobotics has reiterated its total revenue guidance to be approximately $325.5 million, representing a strong 45% growth over the prior year.

• Founded: 2007.
• Core Product: AquaBeam/HYDROS Robotic System.
• 2025 Revenue Guidance: ~$325.5 million.

That kind of growth in a highly specialized medical device market is defintely a signal to pay attention to.

Financial Performance: The Q3 2025 Snapshot

Looking at the latest data, PROCEPT BioRobotics reported a robust third quarter for 2025, which ended September 30. Total revenue for Q3 2025 hit $83.3 million, marking a significant 43% increase compared to the same period last year. The real driver here is the recurring revenue from procedures; U.S. handpiece and consumables revenue-the main product sales-jumped 50% year-over-year to $44.4 million in the quarter.

Here's the quick math on their reach: The company added 58 robotic systems in the quarter, bringing the total U.S. installed base to 653 systems as of September 30, 2025. Gross margin also expanded to 65% in Q3 2025, up from 63% in the prior year, showing improved operational efficiencies. What this estimate hides, still, is that they are not yet profitable; the net loss for the quarter was $21.4 million, though the adjusted EBITDA loss improved to $7.4 million.

A Leader in Urological Robotics

PROCEPT BioRobotics is quickly establishing itself as a leader in the surgical robotics industry, particularly within the urology niche. Their unique Aquablation therapy is the first and only image-guided robotic therapy for BPH, which gives them a distinct competitive edge. The company's focus on a high-volume, chronic condition like BPH-which affects millions of men-positions them for sustained procedural growth as their installed base of systems expands. International revenue growth also looks strong, increasing by 53% to $9.4 million in Q3 2025.

Their success isn't just about selling the robot; it's about the adoption of the therapy itself. They are strategically focused on accelerating utilization and new account launches to maximize the use of those 653 installed systems. If you want to dive deeper into the institutional backing and market sentiment behind this growth story, you should check out Exploring PROCEPT BioRobotics Corporation (PRCT) Investor Profile: Who's Buying and Why?

PROCEPT BioRobotics Corporation (PRCT) Mission Statement

You're looking for the bedrock of a high-growth surgical robotics company, and for PROCEPT BioRobotics Corporation (PRCT), that foundation is clear: they aim to redefine urology. Their mission is to revolutionize Benign Prostatic Hyperplasia (BPH) treatment globally in partnership with urologists by delivering best-in-class robotic solutions that positively impact patients and drive value.

This mission isn't just a plaque on the wall; it's the strategic filter for every dollar spent and every product iteration, especially as they scale. Their vision is equally ambitious: to restore patient lives by delivering the BPH treatment of choice. This dual focus on patient outcome and market leadership is what guides their aggressive growth, which projects a total revenue of approximately $325.5 million for the full year 2025, representing a strong 45% growth over the prior year. [cite: 1, 3, 4, 5 in step 1]

For a deeper dive into the market dynamics driving this performance, you should check out Exploring PROCEPT BioRobotics Corporation (PRCT) Investor Profile: Who's Buying and Why?

Core Component 1: Excellence in Robotic Solutions

The first core component of their mission-delivering best-in-class robotic solutions-is anchored in their core value of Excellence. This means consistently providing superior, high-quality products that delight customers, who are both the surgeons and the patients they serve.

The AquaBeam Robotic System, which uses Aquablation therapy (a heat-free waterjet technology), is the concrete example here. This focus on quality and innovation has allowed the company to expand its global installed base to 835 systems as of September 30, 2025. [cite: 2 in step 1] That's a significant footprint for a niche surgical robot, and it reflects the trust hospitals place in the system's precision and safety. If the technology wasn't excellent, that install base wouldn't be growing.

Core Component 2: Ingenuity and Innovation

The goal to 'revolutionize BPH treatment' is driven by the core value of Ingenuity. This is where the company commits to innovation as the driving force behind its success. It's not enough to have a good product; they must constantly push the boundary of what's possible in urology. They're defintely not sitting still.

A great example is the introduction of the HYDROS Robotic System, which incorporates artificial intelligence (AI) features to enhance the predictability and control of Aquablation therapy. [cite: 14 in step 1] This innovation is what fuels their recurring revenue stream. Here's the quick math: U.S. handpiece and consumables revenue-the recurring, high-margin part of the business-hit $44.4 million in Q3 2025 alone, a 50% year-over-year increase. [cite: 3, 5 in step 1] That kind of growth in consumables shows strong procedural adoption, which is the ultimate proof of a truly ingenious solution.

Core Component 3: Driving Value for Patients and Shareholders

The final pillar, to 'positively impact patients and drive value,' connects the clinical mission directly to financial performance through the core value of Drive. This means having a purpose-driven passion to succeed, which extends to maximizing enterprise value for stockholders.

For patients, the value is clear: a treatment for BPH that offers durable symptom relief with a low risk of sexual function or continence side effects. [cite: 8 in step 1] For investors, the value is demonstrated by the improving operating metrics. The company's gross margin expanded to 65% in Q3 2025, a critical sign of operational efficiency and pricing power for a medical device company. [cite: 2, 5 in step 1] What this estimate hides, of course, is the continued net loss-an accumulated deficit of $611.7 million year-to-date 2025-which reminds us that this is still a high-growth, capital-intensive play. [cite: 2 in step 1] Still, the improved gross margin provides a clear path to future profitability.

• Finance: Monitor gross margin for Q4 2025 to ensure it stays above the 64.0% guidance floor. [cite: 3 in step 1]

PROCEPT BioRobotics Corporation (PRCT) Vision Statement

You're looking at PROCEPT BioRobotics Corporation (PRCT) and trying to figure out if their stated goals align with the financial reality. The direct takeaway is this: their vision is clear-to become the definitive, first-choice treatment for benign prostatic hyperplasia (BPH)-and their 2025 financials show aggressive execution, but also the high cost of that market capture.

The company's strategy is a classic growth-over-profit play right now. They are spending heavily to plant their robotic systems in hospitals, which is why they are on track for a full-year 2025 revenue of approximately $325.5 million, representing about 45% growth over 2024, but also projecting an Adjusted EBITDA loss of approximately ($35.0) million for the year. That's the trade-off for a company focused on a long-term vision of market dominance. You need to see the vision as a strategic roadmap for how they intend to reverse that loss later.

Vision: Restoring Patient Lives by Delivering the BPH Treatment of Choice

The vision is simple: be the best, not just one of the options. PROCEPT BioRobotics Corporation aims to restore patient lives by delivering the BPH treatment of choice. This isn't just about selling their Aquablation therapy; it's about establishing a new standard of care that urologists and patients prefer over older methods like transurethral resection of the prostate (TURP).

The near-term opportunity is in their installed base. As of September 30, 2025, they had 653 robotic systems installed in the U.S.. This is the foundation for their razor-and-blade model. The risk? If procedural volume per system doesn't increase fast enough, the capital expense of placing those 213 new robotic systems expected to be sold in the U.S. in 2025 will weigh heavily on the balance sheet. The gross margin of 64.0% to 64.5% for 2025 is solid, but the operating expenses of approximately $302.0 million are what's driving the net loss. That's the cost of educating the market and building out the commercial team. It's a land grab.

Mission: Revolutionize BPH Treatment Globally and Drive Value

The mission statement is more actionable: to revolutionize BPH treatment globally in partnership with urologists by delivering best-in-class robotic solutions that positively impact patients and drive value. This breaks down into three clear components: global expansion, urologist partnership, and driving shareholder value.

Global expansion is showing early traction, with international revenue for Q3 2025 at $9.4 million, a 53% increase year-over-year. They are expecting full-year international revenue to hit approximately $37.5 million, representing 56% annual growth. That's defintely a strong signal that the technology resonates outside the U.S. The U.S. handpiece and consumable revenue of $44.4 million in Q3 2025, up 50% year-over-year, shows the urologist partnership is paying off in procedural volume-that's the core of their recurring revenue stream. The key is to keep that recurring revenue growing faster than the one-time system sales. To be fair, the company's strong liquidity, with a current ratio of 9.21, gives them a solid cushion to execute this mission before needing to tap capital markets again.

For a deeper dive into how this growth is impacting the balance sheet, you should look at Breaking Down PROCEPT BioRobotics Corporation (PRCT) Financial Health: Key Insights for Investors.

Core Values: The ExCITED Framework for Execution

A company's values, summed up in their acronym ExCITED, show you the culture they are building to execute the mission. This framework is what turns the strategy into daily action.

• Excellence: Delight customers with superior, high-quality solutions. This is reflected in their gross margin expanding to 65% in Q3 2025, up from 63% in the prior year, showing operational efficiency is improving even with rapid growth.
• Commitment: Embrace ownership, accountability, and dedication. The recent executive leadership transition in July 2025, while costly in the short term, points to a commitment to finding the right long-term leadership to drive accountability for the 2026 revenue guidance of $410 million to $430 million.
• Ingenuity: Innovation is the driving force behind success. They are leveraging their HYDROS™ Robotic System, which is the only AI-Powered robotic technology delivering Aquablation therapy, to differentiate themselves in a competitive surgical robotics market.
• Teamwork: Collaboration and respect are paramount.
• Ethics: Require integrity, honesty, and transparency in every task.
• Drive: Share a drive to succeed with purpose-driven passion.

Here's the quick math on the risk: the net loss for the nine months ended September 30, 2025, was $65.73 million. That's a lot of cash burn, but it is a calculated investment into building a market that they believe will eventually generate high-margin, recurring revenue from those handpieces and consumables. The values, particularly 'Drive' and 'Ingenuity,' are what you need to see in their R&D spending to ensure they maintain their technological edge and justify that burn rate.

PROCEPT BioRobotics Corporation (PRCT) Core Values

You're looking past the quarterly noise to understand the foundational principles driving PROCEPT BioRobotics Corporation's (PRCT) growth, and that's smart. The company's core values, encapsulated in the acronym ExCITED, are not just wall posters; they are the operational map for their strategy in the surgical robotics space. This framework helps us map their near-term risks and opportunities to clear, actionable performance, especially when you consider their ambitious 2025 financial guidance.

The whole point is to revolutionize BPH (benign prostatic hyperplasia) treatment globally, and their values show exactly how they plan to pull it off. They're a trend-aware realist, focused on execution. For a deeper dive into the market perspective, you should check out Exploring PROCEPT BioRobotics Corporation (PRCT) Investor Profile: Who's Buying and Why?.

Excellence: Delivering Superior, High-Quality Solutions

Excellence, for PROCEPT BioRobotics, means delivering superior solutions that delight customers-the urologists and, ultimately, the patients. In financial terms, this commitment to quality shows up in their margin performance. The company's continued focus on manufacturing and clinical outcomes is what drives their gross margin (the profit left after cost of goods sold). For the third quarter of 2025, they reported a gross margin of 64.8%, an increase of 160 basis points year-over-year. That's a defintely strong signal of cost control and value pricing for their Aquablation therapy.

This metric is critical. A high gross margin, with a full-year 2025 expectation in the range of 64% to 64.5%, means their product is highly valued and their manufacturing is efficient. Sustained margin performance is the clearest sign that their robotic systems, like the HYDROS™ Robotic System, are indeed best-in-class, not just a commodity. Superior quality equals pricing power.

Commitment: Embracing Ownership and Accountability

Commitment is about owning the outcome, from the sales floor to the operating table. This value is best demonstrated by the company's clear, reaffirmed financial targets and the organizational changes put in place to hit them. Management has reiterated a full year 2025 total revenue expectation of approximately $325.5 million, representing a robust growth of approximately 45% compared to 2024.

To ensure they meet this target, they've launched multiple initiatives aimed at improving commercial execution, including organizational restructuring and the appointment of a new Chief Marketing and Strategy Officer. Here's the quick math on their capital sales: they expect to sell approximately 213 new robotic systems in the U.S. in 2025, plus approximately 52,000 handpieces. That level of accountability requires everyone to embrace ownership, especially when accelerating new account launches, a key focus area to drive utilization.

Ingenuity: Driving Innovation and Creativity

Ingenuity is the lifeblood of a surgical robotics company. It's what separates them from legacy treatments. PROCEPT BioRobotics embodies this with its continuous investment in R&D and product evolution. Their HYDROS™ Robotic System is a concrete example, incorporating AI-Powered technology to deliver Aquablation therapy, enhancing precision and outcomes.

But they are not stopping at BPH. Ingenuity also means looking ahead to new applications. The company is actively studying the potential of Aquablation for prostate cancer in the WATER-IV clinical trial. This is a significant, forward-looking commitment to innovation that aims to expand their addressable market beyond BPH, which impacts approximately 40 million men in the United States.

Teamwork, Empathy, and Drive: Focusing on Patient and Global Impact

The remaining values-Teamwork, Empathy, and Drive-are all interwoven into their commercial and international expansion strategy. They understand that a great product is nothing without great execution and a focus on the patient. Empathy, in this context, translates to patient activation and market awareness. They are launching Direct-to-Consumer (DTC)-style outreach to ensure patients know about Aquablation therapy, not just relying on the physician.

Teamwork and Drive are evident in their international push. They've raised their full-year 2025 international revenue guidance to approximately $37.5 million, representing a 56% annual growth. This accelerated international growth requires a focused, concerted effort across sales, marketing, and logistics. It's a clear action point: expand globally to help more patients. What this estimate hides, still, is the variability in new account launch times, which they are actively working to accelerate for better procedure utilization.